Literature DB >> 32953959

Perniolike lesions and coagulopathy in a patient with COVID-19 infection.

Goran Micevic1, Jensa Morris2, Alfred Ian Lee3, Brett A King1.   

Abstract

Entities:  

Keywords:  COVID toes; COVID-19; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SARS-CoV2; chilblains

Year:  2020        PMID: 32953959      PMCID: PMC7491482          DOI: 10.1016/j.jdcr.2020.08.042

Source DB:  PubMed          Journal:  JAAD Case Rep        ISSN: 2352-5126


× No keyword cloud information.

Introduction

Perniolike lesions of the toes that are caused by coronavirus disease 2019 (COVID-19), known as COVID toes, have recently been reported around the world.1, 2, 3 The etiology and optimal management remain largely unknown. We present the case of a patient with COVID toes in association with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in whom a comprehensive hematologic evaluation revealed a striking elevation of factor VIII activity and von Willebrand factor level, suggesting that endothelial dysfunction may be associated with this cutaneous manifestation of coronavirus infection.

Case report

A 77-year-old woman with history of hypertension, Alzheimer dementia, and adrenal insufficiency was admitted to the hospital for lethargy and acute kidney injury in the setting of a urinary tract infection with Enterococcus faecalis. At admission, a polymerase chain reaction test result for SARS-CoV-2 was negative. She was afebrile and vital signs were normal on room air. She was treated with appropriate antibiotics and intravenous fluids, with restoration of baseline kidney function and mental status, and was preparing for hospital discharge when a repeated polymerase chain reaction test was positive for SARS-CoV-2. She did not exhibit any respiratory symptoms and a chest radiograph showed no focal findings. At that time, inflammatory markers were notable for elevated levels of C-reactive protein (10.6 mg/L, normal <3 mg/L), ferritin (587 ng/mL, normal <150 ng/mL), D-dimer (1.49 mg/L, normal <0.77 mg/L), and fibrinogen (501 mg/dL, normal 136-464 mg/dL). Electrolyte levels, complete blood cell count, prothrombin levels, partial thromboplastin time, and international normalized ratio were within normal limits. A cytokine panel result including interleukin 2, 4, 5, 8, 12, 13, and 17; interferon γ; tumor necrosis factor α; and interleukin 2R was unremarkable. She did not meet institutional criteria for hydroxychloroquine or tocilizumab treatment. Six days after the positive polymerase chain reaction test, she developed violaceous patches, some retiform, involving the bilateral aspect of the plantar and dorsal toes and feet (Fig 1). The rash was nontender and there was no involvement of skin elsewhere. The differential diagnosis included perniolike lesions and early/evolving retiform purpura associated with COVID-19.
Fig 1

Appearance of perniolike rash on dorsal and plantar aspects of the feet.

Appearance of perniolike rash on dorsal and plantar aspects of the feet. Laboratory evaluation results, including antinuclear antibody, C3, C4, cryofibrinogen, and total complement, were negative. Repeated cytokine panel result was notable for elevation of interleukin 2R level (1565 pg/mL, normal <1033 pg/mL). A hypercoagulability evaluation was consistent with a prothrombotic state, with elevated levels of thrombin-antithrombin complexes (11.3 μg/L, normal <4 μg/L), factor VIII activity (430.8%, normal 66%-143%), von Willebrand factor antigen (612%, normal 62%-175%), von Willebrand factor activity (>390%, normal 58%-163%), and plasminogen activator inhibitor 1 activity (96 ng/mL, normal 4-43 ng/mL). There was no evidence of lupus anticoagulant. The magnitude of elevation in von Willebrand factor and factor VIII was much greater than that in other patients with mild SARS-CoV-2 in our hospital and more similar to that observed in patients with severe SARS-CoV-2 at our hospital who were receiving mechanical ventilation because of acute respiratory distress syndrome (data not shown). Therapeutic anticoagulation was considered, but the patient continued to receive prophylactic low-molecular-weight heparin, which had been started at hospital admission. The rash resolved during the subsequent 72 hours, and no thromboembolic events were reported at 1-month follow-up.

Discussion

Perniolike lesions, or COVID toes, are emerging as a relatively common observation in association with the COVID-19 pandemic.1, 2, 3 The etiology, timeline, and optimal management remain poorly understood. Recent articles by Manalo et al and Parodi et al appropriately discuss potential hematologic abnormalities that may be underlying cutaneous findings observed in COVID-19. Parodi et al posed the important question of whether coagulopathy in COVID-19 patients is a manifestation of mild or severe antiphospholipid syndrome. Herein, in collaboration with hematology colleagues, we report a case of COVID toes with a benign clinical course, but with striking elevation in factor VIII activity and von Willebrand factor levels. SARS-CoV-2 has been detected in endothelial cells of COVID-19 patients and has been proposed to cause endothelial dysfunction and increased risk of thromboembolic disease. Elevation of plasma von Willebrand factor level is an established marker of endothelial activation and injury, and is significantly associated with death in acute lung injury. Our findings suggest that perniolike lesions may be associated with endothelial dysfunction, typically observed in critical illness and similar to that believed to occur in acute respiratory distress syndrome. However, the juxtaposition of a hypercoagulability profile typically observed in critical illness and a benign clinical course presented here highlights the complexity of the pathobiology of this disease manifestation. The factors that contribute to a benign course (eg, perniolike lesions) versus a severe coagulopathy, such as disseminated intravascular coagulation or pulmonary embolism are presently unknown. Although our report is limited by lack of histopathology, others have reported lymphohistiocytic perivascular inflammation and cutaneous microthrombi in association with COVID-19 infection., We hope that this report, together with others, will inform larger studies and additional collaboration of dermatologists and hematologists to further elucidate the diagnosis, prognosis, and pathophysiology of cutaneous and systemic manifestations of COVID-19.

Conclusion

Herein, we describe a case of COVID toes in association with striking elevations in factor VIII activity and von Willebrand factor level. Our findings suggest that endothelial dysfunction may be associated with perniolike lesions reported in cases of novel coronavirus infection. Further collaboration between dermatologists and hematologists may be critically important to advance our understanding of cutaneous manifestation of novel coronavirus infection and improve patient care.
  10 in total

1.  Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury.

Authors:  Lorraine B Ware; Mark D Eisner; B Taylor Thompson; Polly E Parsons; Michael A Matthay
Journal:  Am J Respir Crit Care Med       Date:  2004-06-16       Impact factor: 21.405

2.  Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Authors:  Alice Huertas; David Montani; Laurent Savale; Jérémie Pichon; Ly Tu; Florence Parent; Christophe Guignabert; Marc Humbert
Journal:  Eur Respir J       Date:  2020-07-30       Impact factor: 16.671

3.  Could antiphospholipid antibodies contribute to coagulopathy in COVID-19?

Authors:  Aurora Parodi; Giulia Gasparini; Emanuele Cozzani
Journal:  J Am Acad Dermatol       Date:  2020-06-04       Impact factor: 11.527

4.  Chilblain-like lesions on feet and hands during the COVID-19 Pandemic.

Authors:  Nerea Landa; Marta Mendieta-Eckert; Pablo Fonda-Pascual; Teresa Aguirre
Journal:  Int J Dermatol       Date:  2020-04-24       Impact factor: 2.736

5.  A dermatologic manifestation of COVID-19: Transient livedo reticularis.

Authors:  Iviensan F Manalo; Molly K Smith; Justin Cheeley; Randy Jacobs
Journal:  J Am Acad Dermatol       Date:  2020-04-10       Impact factor: 11.527

6.  Coronavirus (COVID-19) infection-induced chilblains: A case report with histopathologic findings.

Authors:  Athanassios Kolivras; Florence Dehavay; Daphné Delplace; Francesco Feoli; Isabelle Meiers; Laurenzo Milone; Catherine Olemans; Ursula Sass; Anne Theunis; Curtis T Thompson; Laura Van De Borne; Bertrand Richert
Journal:  JAAD Case Rep       Date:  2020-04-18

7.  Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic.

Authors:  J López-Robles; I de la Hera; J Pardo-Sánchez; J Ruiz-Martínez; E Cutillas-Marco
Journal:  Clin Exp Dermatol       Date:  2020-08-07       Impact factor: 4.481

8.  Retiform purpura as a dermatological sign of coronavirus disease 2019 (COVID-19) coagulopathy.

Authors:  X Bosch-Amate; P Giavedoni; S Podlipnik; C Andreu-Febrer; J Sanz-Beltran; A Garcia-Herrera; L Alós; J M Mascaró
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-26       Impact factor: 9.228

9.  Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.

Authors:  Cynthia Magro; J Justin Mulvey; David Berlin; Gerard Nuovo; Steven Salvatore; Joanna Harp; Amelia Baxter-Stoltzfus; Jeffrey Laurence
Journal:  Transl Res       Date:  2020-04-15       Impact factor: 7.012

10.  Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.

Authors:  Yan Zhang; Meng Xiao; Shulan Zhang; Peng Xia; Wei Cao; Wei Jiang; Huan Chen; Xin Ding; Hua Zhao; Hongmin Zhang; Chunyao Wang; Jing Zhao; Xuefeng Sun; Ran Tian; Wei Wu; Dong Wu; Jie Ma; Yu Chen; Dong Zhang; Jing Xie; Xiaowei Yan; Xiang Zhou; Zhengyin Liu; Jinglan Wang; Bin Du; Yan Qin; Peng Gao; Xuzhen Qin; Yingchun Xu; Wen Zhang; Taisheng Li; Fengchun Zhang; Yongqiang Zhao; Yongzhe Li; Shuyang Zhang
Journal:  N Engl J Med       Date:  2020-04-08       Impact factor: 91.245

  10 in total
  4 in total

1.  The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature.

Authors:  Lucia Novelli; Francesca Motta; Maria De Santis; Aftab A Ansari; M Eric Gershwin; Carlo Selmi
Journal:  J Autoimmun       Date:  2020-12-14       Impact factor: 7.094

Review 2.  Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review.

Authors:  Paolo Gisondi; Sara Di Leo; Francesco Bellinato; Simone Cazzaniga; Stefano Piaserico; Luigi Naldi
Journal:  Dermatol Ther (Heidelb)       Date:  2021-04-02

Review 3.  "COVID toes": A meta-analysis of case and observational studies on clinical, histopathological, and laboratory findings.

Authors:  Kelvin Oliveira Rocha; Virgínia Vinha Zanuncio; Brunnella Alcântara Chagas de Freitas; Luciana Moreira Lima
Journal:  Pediatr Dermatol       Date:  2021-09-13       Impact factor: 1.588

Review 4.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.